---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-24-000199"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:55:58.306735+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Recursion & Exscientia shareholders approve combination; close expected Nov 20

## Summary
- Overwhelming shareholder approval from both Recursion (RXRX) and Exscientia (EXAI) for the proposed combination.
- Transaction expected to close on November 20, 2024, subject to remaining customary conditions.
- Chris Gibson, Ph.D., to remain CEO of the combined company post-closing.
- Update call on Nov 20 at 7:30 a.m. ET; details on X, LinkedIn, YouTube.
- Final voting results to be filed via 8-K and 6-K with SEC.

## SEC filing metadata
- accession: 0001601830-24-000199
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000199/0001601830-24-000199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000199/rxrx-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-24-000199
- JSON: https://secwatch.observer/filing/0001601830-24-000199.json
- Plain text: https://secwatch.observer/filing/0001601830-24-000199.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.